ArticleOncoTargets and therapy2019
Se-Enriched
Article in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Exploring the Beneficial Effects of Se-Methylselenocysteine on GC-1/GC-2 Cells: From Cellular Uptake to Metabolic Pathway Regulation in Male Reproduction.Antioxidants (Basel, Switzerland) · 2026Article
- Effect ofInternational journal of endocrinology · 2026Article
- Effect of Cordyceps militaris extract containing cordycepin on the adipogenesis and lipolysis of adipocytes.FEBS open bio · 2025Article
- Article
- Cordyceps sinensis relieves non-small cell lung cancer by inhibiting the MAPK pathway.Chinese medicine · 2024Article
- Research Progress of Selenium-Enriched Foods.Nutrients · 2023Review
- Natural Sources of Selenium as Functional Food Products for Chemoprevention.Foods (Basel, Switzerland) · 2023Review
- PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate Cancer.Molecular cancer therapeutics · 2021Article
- Novel formulation development from3 Biotech · 2021Review
- Article
- MiR-153-5p Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to Paclitaxel by Inducing G2M Phase Arrest.OncoTargets and therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe anticancer effects of cordyceps on various tumors have been reported. However, little is known about the role of selenium (Se)-enriched
methodsCCK-8 assay was used to determine the appropriate concentrations of Se-enriched
resultsThe concentration of Se-enriched
conclusionThis study demonstrated the inhibitory role of Se-enriched
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.